ImmuCell Corporation (ICCC)

NASDAQ: ICCC · IEX Real-Time Price · USD
5.29
+0.13 (2.52%)
Mar 27, 2024, 4:00 PM EDT - Market closed

Total Valuation

ImmuCell has a market cap or net worth of $41.00 million. The enterprise value is $55.70 million.

Market Cap 41.00M
Enterprise Value 55.70M

Important Dates

The next estimated earnings date is Thursday, May 9, 2024, after market close.

Earnings Date May 9, 2024
Ex-Dividend Date n/a

Share Statistics

ImmuCell has 7.75 million shares outstanding.

Shares Outstanding 7.75M
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Insiders (%) 28.25%
Owned by Institutions (%) 13.50%
Float 5.53M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 2.52
Forward PS n/a
PB Ratio 1.58
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 3.42
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.59, with a Debt / Equity ratio of 0.64.

Current Ratio 3.59
Quick Ratio 1.16
Debt / Equity 0.64
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -22.60% and return on invested capital (ROIC) is -14.94%.

Return on Equity (ROE) -22.60%
Return on Assets (ROA) -14.30%
Return on Capital (ROIC) -14.94%
Revenue Per Employee $226,203
Profits Per Employee -$87,537
Employee Count 72
Asset Turnover 0.37
Inventory Turnover 2.00

Taxes

In the past 12 months, ImmuCell has paid $4,789 in taxes.

Income Tax 4,789
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +9.07% in the last 52 weeks. The beta is 0.59, so ImmuCell's price volatility has been lower than the market average.

Beta (1Y) 0.59
52-Week Price Change +9.07%
50-Day Moving Average 5.19
200-Day Moving Average 5.07
Relative Strength Index (RSI) 55.70
Average Volume (30 Days) 7,332

Short Selling Information

The latest short interest is 6,384, so 0.08% of the outstanding shares have been sold short.

Short Interest 6,384
Short Previous Month 6,316
Short % of Shares Out 0.08%
Short % of Float 0.12%
Short Ratio (days to cover) 0.84

Income Statement

In the last 12 months, ImmuCell had revenue of $16.29 million and -$6.30 million in losses. Loss per share was -$0.81.

Revenue 16.29M
Gross Profit 3.60M
Operating Income -6.38M
Pretax Income -6.30M
Net Income -6.30M
EBITDA -3.65M
EBIT -6.30M
Loss Per Share -$0.81
Full Income Statement

Balance Sheet

The company has $1.99 million in cash and $16.68 million in debt, giving a net cash position of -$14.69 million or -$1.90 per share.

Cash & Cash Equivalents 1.99M
Total Debt 16.68M
Net Cash -14.69M
Net Cash Per Share -$1.90
Equity / Book Value 26.01M
Book Value Per Share 3.36
Working Capital 8.63M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$5.25 million and capital expenditures -$3.30 million, giving a free cash flow of -$8.55 million.

Operating Cash Flow -5.25M
Capital Expenditures -3.30M
Free Cash Flow -8.55M
FCF Per Share -$1.10
Full Cash Flow Statement

Margins

Gross margin is 22.13%, with operating and profit margins of -39.16% and -38.70%.

Gross Margin 22.13%
Operating Margin -39.16%
Pretax Margin -38.67%
Profit Margin -38.70%
EBITDA Margin -22.42%
EBIT Margin -38.67%
FCF Margin -52.48%

Dividends & Yields

ImmuCell does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield n/a
Shareholder Yield n/a
Earnings Yield -15.37%
FCF Yield -20.85%

Analyst Forecast

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a

Stock Splits

The last stock split was on July 25, 1990. It was a reverse split with a ratio of 1:100.

Last Split Date Jul 25, 1990
Split Type Reverse
Split Ratio 1:100

Scores

ImmuCell has an Altman Z-Score of 1.12 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 1.12
Piotroski F-Score 1